Email Us:
[email protected]
Follow Us On Twitter:
@ JNJInnovation
Visit Our Website
For More Information:
www.jnjinnovation.com
JUNE 2017
PHGB/NPR/0517/0016
© Johnson & Johnson Innovation LLC 2017.
ACCELERATING
INNOVATION
WORLDWIDE
Consumer, Medical Devices, Pharmaceuticals
“Johnson & Johnson Innovation
is about bringing forth highly
differentiated new healthcare
solutions that extend and improve
lives. To do this, we identify the
right partnerships and deal structures,
and allow innovators to leverage
Johnson & Johnson Innovation’s
many resources.”
A Message From
PAUL
STOFFELS,
M.D.
When I took the helm at a small biotechnology
company, Tibotec, my goal was to develop a new
molecular entity that would provide a breakthrough
in combating multidrug-resistant forms of HIV.
I approached this opportunity to change the way
HIV/AIDS is treated – not just as a physician in Africa
where I started my career in medicine, but also as a
scientist, an innovator and an entrepreneur.
advance science and technology at all stages of innovation.
However, I quickly discovered that the task of bringing new and
Fundamentally, Johnson & Johnson Innovation is about bringing forth
differentiated medicine to patients globally is not an easy one.
highly differentiated new healthcare solutions that extend and improve
It requires more than great science, tenacity and a good business
lives, not just through therapeutics, but also medical devices, consumer
plan. Without the help of strong collaborators who can offer
products and integrated “beyond the pill” solutions. To do this, we identify
complementary expertise, it is nearly impossible.
the right partnerships and deal structures, and allow innovators to leverage
When we launched Johnson & Johnson Innovation – first with Innovation
Centers in California, Boston, London and Asia Pacific – our aim was
to contribute to the robust regional innovation ecosystems around the
world, and to do so by meeting the needs of entrepreneurs and scientists
working in the areas of medical technologies, consumer healthcare
technologies and therapeutics. Today, Johnson & Johnson Innovation
brings together business development, venture investment, incubation and
Research & Development (R&D) resources from across our company to
Johnson & Johnson’s many resources. Providing the right kind of support
Today, Tibotec is part of Johnson & Johnson. The relationship
for new ideas is critical to driving innovation and achieving our goals
between Tibotec and Johnson & Johnson has led to the successful
to transform world health. We look forward to getting to know you and
development and launch of transformative HIV medications that have
working with you to push the boundaries of what science and medicine
improved the quality of life and significantly extended the lives of
can achieve.
people all over the world who are living with HIV.
Paul Stoffels, M.D.
Chief Scientific Officer, Johnson & Johnson
VISION:
OUR
APPROACH
Positively impact human
health through innovation.
MISSION:
Create the leading global
innovation network to
generate transformational
healthcare solutions through
value-creating partnerships.
Table of Contents
Areas of Interest ________________________________________________________________________ 01
Company Incubation ___________________________________________________________________ 03
Innovation Centers _____________________________________________________________________ 05
Investing ___________________________________________________________________________________ 07
Business Development _______________________________________________________________ 09
Research & Development ____________________________________________________________ 11
Global Public Health ___________________________________________________________________ 15
Contact Us ________________________________________________________________________________ 17
Pharmaceuticals
Medical Devices
Consumer
CARDIOVASCULAR & METABOLISM
CARDIOVASCULAR
BABY CARE
- Diabetes
- Atrial Fibrillation
BEAUTY
- Thrombosis
- Structural Heart Conditions
- Body Care
IMMUNOLOGY
- Hemorrhagic and Ischemic Stroke
- Facial Skin Care
- Rheumatoid Arthritis
ONCOLOGY
- Sun Care
- Inflammatory Bowel Disease
- Improved Treatment Options
COMPROMISED SKIN
- Psoriasis
- Minimally Invasive Procedures
INFECTIOUS DISEASES & VACCINES
OBESITY
We are looking for ideas that align with our business priorities
- Hepatitis
- More Durable Interventions
in our Pharmaceuticals, Consumer and Medical Devices sectors.
- Respiratory Infections
- Prevent or Reduce Morbidities
In each sector, we focus on specific areas of interest that have
NEUROSCIENCE
OSTEOARTHRITIS
- Mood Disorders
- Early Interventions
- Alzheimer’s Disease
- Better Surgical Outcomes
ONCOLOGY
OSTEOPOROSIS
- Prostate Cancer
- Minimize Osteoporosis Fracture Rate
- Lung Cancer
- Improve Healing
AREAS OF
INTEREST
the greatest potential to improve the lives of patients and
consumers, and contribute to our business.
- Hematologic Malignancies
FEMININE PERSONAL CARE
ORAL CARE
OTC
- Allergy Care
- Cough & Cold Care
- Pain Care
- Digestive Health
- Smoking Cessation
VISION CARE
DIABETES
3D PRINTING
DIGITAL SURGERY
JOHNSON & JOHNSON INNOVATION
|
01
JOHNSON & JOHNSON INNOVATION
|
02
Through our own facilities and a network of collaborations,
JLINX: Venture Funding,
Expertise and Facilities in Belgium
our partners have access to an array of lab, office and other
COMPANY
INCUBATION
Located in a fully dedicated facility on the Janssen Campus
resources including:
in Beerse, Belgium, venture-based Johnson & Johnson
- State-of-the-art equipment and core research labs including
device and digital prototype labs for efficient discovery across
therapeutics, devices and consumer applications
Innovation, JLINX (JLINX) offers startups a spectrum of
We understand the challenges of getting a life sciences company up and
- Year-round innovator curriculum focused on commercial
and business development
We offer a wide range of educational and funding programs, as
well as facilities and services to help startup companies thrive.
running, which is why Johnson & Johnson Innovation provides a number
of company incubation options for our partners around the globe.
INCUBATORS
140+
companies in residence
10
facilities around the globe
30+
deals with J&J Family of Companies
JOHNSON & JOHNSON INNOVATION
|
- Single bench tops, modular labs and office space with flexible
terms for entrepreneurs to get started and grow
flexible ways to grow and collaborate across the European
life sciences ecosystem.
CDI @ TMC
The Center for Device Innovation @ Texas Medical Center
(CDI @ TMC) is a new collaboration (opening late 2017) that
JLABS: A Big Company Platform
for Emerging Healthcare Companies
With facilities in San Diego, San Francisco, South San Francisco,
Cambridge, Mass., Lowell, Mass., Houston and Toronto,
Johnson & Johnson Innovation, JLABS (JLABS) provides a
capital-efficient, resource-rich environment where emerging
companies can transform the scientific discoveries of today into
aims to accelerate end-to-end development of breakthrough
medical devices. CDI’s state-of-the-art engineering capabilities
are partnered with TMC’s scientific and clinical facilities to
accelerate new medical technologies from concept through
commercialization. CDI will be home to R&D staff of the
Johnson & Johnson Medical Device Companies and will be
used to accelerate select internal projects and strategically
aligned ventures of startup partner companies.
the breakthrough healthcare solutions of tomorrow. With room
for more than 250 companies across our seven sites, JLABS
offers a wide range of educational and funding programs, as
well as facilities and services to help startup companies thrive.
JLABS is a “no-strings-attached” model, giving innovators the
freedom to build value.
03
JOHNSON & JOHNSON INNOVATION
|
04
Our Innovation Centers
If you are in academia or with an early-stage consumer,
medical device, or biopharmaceutical company seeking
INNOVATION
CENTERS
The teams located at the Johnson & Johnson Innovation Centers
a collaboration to advance a novel program, make the
connection with our Johnson & Johnson Innovation team.
Our regional Innovation Centers are located around the
globe in the life sciences hot spots of Asia Pacific, Boston,
California and London. Each Innovation Center houses
deal structures including:
beginning at inception through all stages of development. We are seeking
- Early-stage research funding
innovations with the potential to make a transformational impact in the
- Licensing and collaborations
health and lives of people around the globe.
- Equity investments
- Cross-sector expertise
|
05
BOSTON
LONDON (EMEA)
ASIA PACIFIC
dealmaking capabilities, with flexibility to engineer several
are dedicated and focused on accessing innovation from all sources
JOHNSON & JOHNSON INNOVATION
CALIFORNIA
science and technology experts, and has full and broad
JOHNSON & JOHNSON INNOVATION
|
06
INVESTING
As the oldest corporate venture fund in the life sciences industry,
Johnson & Johnson Innovation – JJDC has been making strategic
JJDC: Driving Innovation
Through Venture Investing
JJDC has invested in hundreds of emerging life sciences
companies developing healthcare solutions in areas of
strategic interest to the Johnson & Johnson Family of
At JJDC, we believe strongly in value-add investing and
play an active role in the companies in which we invest.
Through this, we provide strategic direction and access to
internal experts across the Johnson & Johnson Family of
Companies. Our ultimate goal is to help grow Johnson &
Johnson’s pipeline with innovative products.
Companies, and it plays a key role in the company’s
strategy to bring new healthcare products to the people
venture and equity investments in life sciences innovations for
who need them.
over 40 years.
Located within the Innovation Centers, JJDC has visibility
to a wide range of opportunities in pharmaceutical, biotech,
VENTURE FUNDING
40
+
year legacy
24
new investments in 2016
200 M+
$
medical devices and consumer healthcare investing.
JJDC does not believe in a one-size-fits-all approach.
We understand that each company is unique and requires an
equally distinct investment strategy. We invest at all stages,
ranging from seed funding and Series A investments in the
earliest-stage startups to Series B investments and beyond
in more mature companies, each deal customized to fit the
opportunity. We make private investments in public equity to
support licensing deals.
deployed in 2016
JOHNSON & JOHNSON INNOVATION
|
07
JOHNSON & JOHNSON INNOVATION
|
08
Our approach meaningfully integrates dealmakers
and objectives, focusing on the success of the business,
with science and business leaders. This allows us to
product or technology. This approach has helped to position
shape better deals and achieve faster approvals and
the Johnson & Johnson Medical Devices Companies as
in-market impact. Since no two deals are exactly alike,
partners of choice.
Janssen Business Development employs a flexible and
BUSINESS
DEVELOPMENT
Midsize to Large Biotech and Established
Pharmaceutical Companies:
Janssen Business Development
If you are with an established pharmaceutical company or midsize to large biotechnology
company, seeking collaboration or merger and acquisition discussions, make the
connection with Johnson & Johnson Innovation – Janssen Business Development.
We seek to identify the partner opportunities that will solve unmet needs and create
real value in Janssen’s five therapeutic areas of focus: Cardiovascular & Metabolism,
Immunology, Infectious Diseases & Vaccines, Neuroscience and Oncology. We seek
adaptive approach to tailor an optimal deal structure to
each unique partner opportunity.
Our goal is to form active partnerships in which we can
bring the full strength of Johnson & Johnson to bear to
create a long and valuable relationship and transformational
differentiated products.
Established Consumer
Healthcare Companies
Johnson & Johnson Family of Consumer Companies
believes in caring for people around the world by
anticipating their needs and creating solutions and
experiences that help them and those they care for live
Established Medical
Device Companies
Our approach to partnering is rooted in open communication,
sound implementation, and solid relationships with our
partners built on trust, recognition and mutual respect.
Working with the Johnson & Johnson Medical Devices
Companies gives you access, resources, expertise and
commitment that you simply can’t find anywhere else.
healthy, vibrant lives. To achieve this goal, our experts within
the Innovation Centers, Consumer Business Development
and JJDC are actively exploring the best science and
technology to support consumer healthcare businesses.
We are interested in novel, game-changing ingredients
as well as complete new products (including devices)
and solutions. Our collaborators have the opportunity
to leverage our strong R&D, marketing, regulatory and
manufacturing capabilities, as well as our global footprint.
These capabilities – honed through the development of
relationships with partners who desire collaborations with transparency and openness,
Our legacy of establishing and fostering productive
some of the best-known brands in the world – are part of
which we believe leads to new ideas and better solutions.
relationships with key external stakeholders globally is an
each conversation.
integral part of our strategy. Each partnership is built on
a shared vision with well-defined and agreed-upon goals
JOHNSON & JOHNSON INNOVATION
|
09
JOHNSON & JOHNSON INNOVATION
|
10
RESEARCH &
DEVELOPMENT
Johnson & Johnson is a broadly based global healthcare company
with expertise in all stages of research and development of large- and
small-molecule therapeutics, vaccines, medical devices and consumer
products. We work with our collaborators across our therapeutic areas
to provide a wide range of R&D support, from discovery and early
development through clinical trial design and regulatory strategy.
Johnson & Johnson Medical
Devices Research & Development
Johnson & Johnson Consumer
Research & Development
Our Johnson & Johnson Medical Devices Companies have a
Johnson & Johnson Consumer Inc., known for its iconic
long history of successes in creating new markets, delivering
brands, is one of the largest and most scientifically driven
breakthrough innovation, and introducing leading technologies
consumer businesses in the world. Most of our products
for the benefit of our customers, our physician partners and
are endorsed as No. 1 in their category by healthcare
the patients we serve. We do this by coupling our global
professionals. Our R&D capabilities are world-class and
commercial footprint and broad internal innovation in areas
focused on providing scientifically and clinically proven
such as Research & Development, Regulatory Affairs and
solutions for consumer needs. Our R&D is strategically
Health Economics with innovation sourced externally.
organized around consumer needs, such as Sun Care,
Through close collaboration across our Business Development
Facial Skin Care, Wound Care, Oral Care and Pain Care.
team, our Office of Medical Science and Technology and
We deliver products and solutions grounded in deep
our broader Johnson & Johnson Innovation organization –
consumer insights and backed by strong research.
including JJDC – we seek the best science and technology,
We seek important new technologies and solutions that
wherever it is, to address unmet medical needs. Our strategic
can be accelerated to consumers through co-creation
approach to portfolio management supports our innovation
with external innovators and our internal R&D teams. With
agenda, which is focused on these needs, including surgical
a focus on our key strategic areas, our External Innovation
oncology, obesity, select cardiovascular disease areas,
team, Business Development team and broader Johnson
osteoarthritis and osteoporosis.
& Johnson Innovation organization seek opportunities from
around the world – no matter where the idea might be.
JOHNSON & JOHNSON INNOVATION
|
11
JOHNSON & JOHNSON INNOVATION
|
12
Janssen Research & Development
DISEASE INTERCEPTION ACCELERATOR
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we work closely with external partners to discover and develop
integrate innovative science, novel therapeutics, precision
healthcare solutions that address significant medical needs and transform the lives of patients around the world. Examples include:
diagnostics and new business models to address susceptibility
Scientists with the Disease Interception Accelerator seek to
to disease and to create solutions to intervene earlier and
intercept progression to disease.
JANSSEN DISCOVERY SCIENCES
JANSSEN R&D OPERATIONS
Focused on small-molecule drug discovery, Janssen
Experts from Janssen R&D Operations develop our drug
Discovery Sciences conducts cutting-edge research from
candidates, conduct clinical trials around the world and
JANSSEN HUMAN MICROBIOME INSTITUTE
target identification and lead discovery through preclinical
formulate large- and small-molecule medicines, continuously
The Janssen Human Microbiome Institute focuses on
safety assessment in order to discover and develop
improving performance, shortening development timelines
accelerating the translation of rapidly emerging microbiome
transformational medicines.
through exceptional execution and bringing medicines to people
science, which deals with the diverse population of bacteria
in need faster.
living in and on the human body, into breakthrough solutions
that promote health.
JANSSEN BIOTHERAPEUTICS
Janssen Biotherapeutics (JBIO) is a leader in the discovery
JANSSEN DIAGNOSTICS
and development of monoclonal and next-generation
Janssen Diagnostics focuses on both companion and
JANSSEN PREVENTION CENTER
antibodies to treat complex diseases, providing end-to-end
complementary diagnostics, developing and leveraging the
Scientists with the Janssen Prevention Center explore novel
expertise and guidance throughout the various phases of
latest technologies to apply transformational diagnostic tools
approaches to disease prevention by discovering and designing
research and development including life cycle
and methods from the concept stage through commercialization.
healthcare solutions that can keep people healthy and vital for
commercialization strategies.
life. The center focuses on the prevention of chronic diseases
that come with age, which increasingly burden aging populations
and healthcare systems globally.
JOHNSON & JOHNSON INNOVATION
|
13
JOHNSON & JOHNSON INNOVATION
|
14
Building on that foundation, our Global Public Health Organization
OTHERS: Mental health; general surgery and trauma; malaria
is redefining what it means to do business in resource-poor settings
prevention and treatment; pandemic preparedness and emerging
by accelerating innovation and access to broaden our reach and
threats (e.g., Ebola, Zika, etc.).
deepen our impact for those in need.
Leveraging the resources, capabilities and competitive spirit that
GLOBAL
PUBLIC HEALTH
Critical global public health challenges such as TB, HIV, mental
have helped Johnson & Johnson bring good health to a billion
people every day, we have set big goals.
new treatments and vaccines. We are investing in R&D for new HIV
impacted, we are creating comprehensive approaches that aim
treatments and programs to increase access to medicines and quality
to make TB and HIV history and wrestle with several other public
care. We have advanced HIV therapies to potentially help those facing
health challenges.
a lifetime of treatment, and we are investigating strategies in a bid to
achieve a functional cure for HIV. But our ultimate goal is to find
a preventive vaccine for HIV.
Areas of Interest
of delivering impact. As one of the world’s largest healthcare
HIV: Novel and simplified treatment tools, including new
companies, Johnson & Johnson has a legacy of combining
formulations, point-of-care diagnostics and others; innovative
pressing public health challenges of the day.
We support innovation across the continuum of care, to help develop
Through valued partnerships, and working with those directly
health and others seek new leadership, new ideas and faster ways
innovation, science and ingenuity to tackle some of the most
Innovation, Access and Advocacy
prevention tools and strategies, including vaccines, microbicides and
other education/empowerment programs.
To expand access to care, we are collaborating with public and
private organizations. We have a donation program with USAID to
provide 30,000 courses of treatment for MDR-TB in more than
100 countries worldwide. We have also developed a global access
strategy to ensure patients are able to receive treatment, including
national programs with tiered pricing for low- and middle-income
TB: Expanding access to existing regimens for multidrug-resistant
countries, and a global drug facility to provide access to treatment
TB (MDR-TB) while developing simplified treatment regimens and
in 130 countries.
novel molecular approaches; companion diagnostics.
While progress has been made to improve the health of communities
MATERNAL, NEWBORN AND CHILD HEALTH: Obstetric fistula
around the world, there is still work to be done to address the major
repair; preterm birth prevention; maternal/newborn survival;
issues we currently face. Global Public Health is committed to
intestinal worm infections in children.
moving beyond incremental improvement to achieve transformational
outcomes and solve these challenges, once and for all.
JOHNSON & JOHNSON INNOVATION
|
15
JOHNSON & JOHNSON INNOVATION
|
16
Medical Devices Medical Science & Technology
Bruce R. Rosengard, M.D., FRCS
Chief Medical Science Technology Officer
E:
MAKE THE
CONNECTION
Company Incubation/JLABS
Investing/JJDC
Tom Heyman
Head, Johnson & Johnson Innovation, JLABS
President, JJDC
jlabs@ its.jnj.com
E:
Business Development Consumer Medical Devices
Christine Knoblauch
VP, Business Development
E:
cknobla@ its.jnj.com
Consumer Medical Devices Business Development
Melinda Richter
E:
brosenga@ its.jnj.com
info-jjdc@ its.jnj.com
Mano Chinnaswamy
VP, Business Development
E:
mchinna1@ its.jnj.com
Johnson & Johnson
World Headquarters
Innovation Centers
Company Incubation/JLINX
Janssen Business Development
Tom Aelbrecht
Patrick Verheyen
Head, JLINX
Head, Janssen Business Development
E:
jlinx@ its.jnj.com
Innovation Centers
Robert Urban
Head, Johnson & Johnson Innovation
E:
JOHNSON & JOHNSON INNOVATION
jnjinnovation@ its.jnj.com
|
17
E:
pverheye@ its.jnj.com
Medical Devices Business Development
Susan Morano
VP, Business Development
E:
smorano1@ its.jnj.com
Consumer Business Development
Peter Kerrane
Worldwide VP, Strategy &
Business Development
E:
pkerrane@ its.jnj.com
Global Public Health
Jaak Peeters
Head, Global Public Health
E:
jnjglobalpublichealth@ its.jnj.com
Major R&D Facilities
Incubators
Partnering Offices
Leiden
Netherlands
Springhouse
United States
JLABS @ M2D2
Lowell, MA
JLABS @ TMC
Houston, TX
JLABS @ QB3
Bay Area, CA
Beerse
Belgium
Skillman
United States
JLABS @ LabCentral
Boston, MA
JLABS @ San Diego
La Jolla, CA
JLINX
Beerse, Belgium
Beijing
China
Val-de-Reuil
France
JLABS @ Toronto
Toronto, Canada
JLABS @ SSF
South San Francisco, CA
OPENING IN 2018
JLABS @ NYC New York, NY
Global Public
Health Operations
Kenya
Ghana
CDI @ TMC
Houston, TX
FutuRx
Israel
Karolinska Institutet
Sweden
JJI @ QUT
Australia
Singapore
*Our Business Development and Investment teams are co-located at Johnson & Johnson facilities across the globe.
JOHNSON & JOHNSON INNOVATION
|
18